smartdyelivery

est. 2014

Our Vision

" Magical spheres " for the therapy of diseases

Our Vision

„We must learn to create magical spheres that ... only hit the pathogens.”

Paul Ehrlich 1854-1915

With tailor-made nanocarriers, we will set new standards for the targeted, efficient and low-risk use of active pharmaceutical ingredients and other highly potent substances for medical and life science applications.

NEWS

March 26, 2020

PROJECT CONVINCED AND FUNDED IN THE FRAMEWORK OF A ZIM COOPERATION BY BMWI: The Federal Ministry for Economic Affairs and Energy (BMWi) is funding a joint project of the Institute of Organic and Macromolecular Chemistry (IOMC) of Friedrich Schiller University Jena, Prof. Dr. Michael Gottschaldt, the Clinic for Nuclear Medicine and its chief physician Prof. Dr. med. Martin Freesmeyer, and SmartDyeLivery GmbH. The project aims to develop a novel, nanostructured theranostic for applications in oncology.

MARCH 19, 2021

»OPERATION AIR CASTLE« AIR CLEANERS FOR JENA SCHOOLS AND KINDERGARTENS: As part of the Nanotechnology Foundation's »Operation Air Castle« initiative, SmartDyeLivery GmbH has also provided one of 17 air cleaners for schools and kindergartens in Jena, along with other Jena-based companies, private individuals and initiatives. The devices are intended to stop or reduce the spread of the SARS-CoV-2 viruses and thus enable safer teaching or care. The detailed press release can be found here.

January 29, 2021

POLYTARGET PRESENT THEIR NEW IMAGE FILM: Within the framework of the Collaborative Research Center »PolyTarget« of the Deutschen Forschungsgemeinschaft, the co-founders of SmartDyeLivery GmbH (Prof. Dr Ulrich S. Schubert, Prof. Dr med. Michael Bauer and Dr Anja Träger) are developing innovative pharmaceutical polymers and nanoparticles for use in nanomedicine. The image film shows the research work in which the SmartDyeLivery GmbH is a strategic partner.

DEVELOPMENT OF NEW THERAPY OPTIONS

In a first field of application we focus on the targeted transport of active substances in liver cells. We are thus creating a therapeutic option for the treatment of patients with septic cholestasis with the aim of reducing the extremely high mortality rate caused by this complication.